Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2521]

Study reveals genes that may help predict prostate cancer outcomes

Study reveals genes that may help predict prostate cancer outcomes

ASCO GU 2025: Some kidney cancer patients can stop combination treatment after two years

ASCO GU 2025: Some kidney cancer patients can stop combination treatment after two years

ASCO GU 2025: Mobile prostate cancer screening clinic can help address barriers to serving high-risk communities

ASCO GU 2025: Mobile prostate cancer screening clinic can help address barriers to serving high-risk communities

ASCO GU 2025: Talazoparib and enzalutamide combination improves survival in some patients with prostate cancer

ASCO GU 2025: Talazoparib and enzalutamide combination improves survival in some patients with prostate cancer

Novel AI-driven FGFR2/3 inhibitor to overcome resistance tumour mutations

Novel AI-driven FGFR2/3 inhibitor to overcome resistance tumour mutations

Cancer vaccine shows promise for patients with stage III and IV kidney cancer

Cancer vaccine shows promise for patients with stage III and IV kidney cancer

RAD51 biomarker could complement next-generation sequencing in personalizing prostate cancer treatment

RAD51 biomarker could complement next-generation sequencing in personalizing prostate cancer treatment

Study shows urine test for prostate cancer could be used at home

Study shows urine test for prostate cancer could be used at home

Study establishes link between early side effects from prostate cancer radiation and long-term side effects

Study establishes link between early side effects from prostate cancer radiation and long-term side effects

Researchers pioneer DNA-tagged gold nanoparticles for targeted cancer treatment

Researchers pioneer DNA-tagged gold nanoparticles for targeted cancer treatment

More from ecancer